The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Yale Cancer Center study: For Medicaid-covered patients with cancer, insurance does not always mean access

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In a study published in JAMA Network Open, researchers at Yale Cancer Center assessed the acceptance of Medicaid insurance among patients diagnosed with common cancers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Medicaid expansion may improve cancer care and survival for people with HR-negative, HER2-positive breast cancer

New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
Cancer History ProjectGuest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
By Katerina A. Politi and Roy S. Herbst
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account